Novo Nordisk Commits $200 Million to Diabetes Foundation as Buyback Spending Nears DKK 11.8 Billion

Novo Nordisk will direct USD 200 million to the World Diabetes Foundation over the decade spanning 2027 to 2036, a pledge announced Wednesday that fixes the financial scale of its support for diabetes prevention and care in low- and middle-income countries.

The commitment lands alongside a busy stretch of corporate news that has reshaped expectations for the Danish drugmaker — from an improved full-year forecast and a buyback program running well past the two-thirds mark to a pair of partnership shifts and fresh clinical data.

Guidance Raised as Third-Quarter Sales and Profit Grow

On November 4, Novo Nordisk lifted its outlook for adjusted revenue and adjusted operating profit. At constant exchange rates, it now projects both measures to move between -2% and +2% in 2026, a marked improvement on the prior range of -6% to 0%.

The upgrade followed third-quarter 2026 results showing adjusted revenue of DKK 79.2 billion, up 4% at constant currencies. Adjusted operating profit came in at DKK 31.72 billion, a 27% increase on the same basis.

Buyback Total Reaches 42.6 Million B-Shares

Share repurchases have continued apace. Novo Nordisk disclosed Monday that it had bought back roughly 42.6 million B-shares between February 4 and November 6, at a total cost of about DKK 11.8 billion.

The most recent tranche, reported the same day, covered 890,000 B-shares acquired for DKK 243.6 million in trades executed between November 3 and November 6.

Semaglutide Shows Liver Benefits in ESSENCE Subgroup

Sunday brought a post-hoc analysis of the ESSENCE trial. Among a subgroup of adults with MASH, liver scarring and a body mass index below 27 kg/m², semaglutide at a 2.4 mg dose delivered improvements over placebo on measures of liver damage, fibrosis and disease activity, according to the company.

Not everyone is convinced the pipeline news justifies a brighter view of the stock. The Deutsche Bank analyst Emmanuel Papadakis reportedly reaffirmed his sell rating on Wednesday, with a price target of DKK 240.

Korro Bio Pact Ends; Abbott to Market Plosbrio in Asia-Pacific

Novo Nordisk also moved on the partnership front. On November 3, it notified Korro Bio that it was terminating their joint cardiometabolic research collaboration and license agreement, without stating a reason. Korro Bio disclosed in a mandatory SEC filing that the cancellation takes effect February 1, 2027.

Two days later came an expansion rather than a retreat: Abbott will market Plosbrio in Singapore and additional Asia-Pacific countries, according to media reports. Novo Nordisk will continue to develop and manufacture the semaglutide product, with Abbott handling commercialization.